4-Sep-2026
Notable healthcare headlines for the week: UnitedHealth, Moderna, and Medtronic in focus
Seeking Alpha News (Sun, 6-Sep 9:05 AM ET)
Ten healthcare stocks leading in year-over-year CapEx growth
Seeking Alpha News (Wed, 2-Sep 8:02 AM ET)
ResMed Launches $450 Million Accelerated Share Repurchase
TipRanks (Tue, 1-Sep 5:24 PM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
PRNewswire (Thu, 27-Aug 4:16 PM ET)
Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference
Globe Newswire (Thu, 27-Aug 4:05 PM ET)
Globe Newswire (Tue, 25-Aug 9:00 AM ET)
Globe Newswire (Mon, 17-Aug 4:10 PM ET)
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Resmed Announces Agreement to Sell MatrixCare Business
Globe Newswire (Tue, 7-Jul 4:30 PM ET)
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
Globe Newswire (Tue, 30-Jun 4:30 PM ET)
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
Resmed trades on the NYSE stock market under the symbol RMD.
As of September 4, 2026, RMD stock price declined to $228.35 with 760,741 million shares trading.
RMD has a beta of 0.23, meaning it tends to be less sensitive to market movements. RMD has a correlation of 0.01 to the broad based SPY ETF.
RMD has a market cap of $32.94 billion. This is considered a Large Cap stock.
Last quarter Resmed reported $1 billion in Revenue and $2.95 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.07.
In the last 3 years, RMD traded as high as $293.81 and as low as $132.24.
The top ETF exchange traded funds that RMD belongs to (by Net Assets): VTI, VOO, VO, SPY, VUG.
RMD has underperformed the market in the last year with a price return of -15.7% while the SPY ETF gained +19.8%. However, in the short term, RMD had mixed performance relative to the market. It has outperformed in the last 3 months, returning +17.9% vs +2.0% return in SPY. But in the last 2 weeks, RMD shares have been beat by the market, returning -1.4% compared to an SPY return of +0.6%.
RMD support price is $223.83 and resistance is $234.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RMD shares will trade within this expected range on the day.